Drug intelligence / Profile preview

WLH-133

Development stage: Preclinical
Lead developer: Wanle Pharmaceutical
Modality: Small Molecules

Overview

WLH-133 is a small molecule chemotherapy agent under development by Shenzhen Wanle Pharmaceutical. It is part of the company's oncology pipeline, which targets a variety of solid and hematologic malignancies, including bladder cancer, breast cancer, leukemia, lymphoma, liver cancer, gastric cancer, and colorectal cancer. As a chemotherapy drug, WLH-133 is designed to treat these cancers through cytotoxic or cytostatic mechanisms, although its specific molecular target and clinical development phase have not been disclosed by the developer.

Beyond the preview

Go deeper on WLH-133.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WLH-133.

Explore the full profile